| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H24O9 |
| Molecular Weight | 420.4099 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(\C=C\C2=CC(O)=CC(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=C2)C=C1O
InChI
InChIKey=GKAJCVFOJGXVIA-DXKBKAGUSA-N
InChI=1S/C21H24O9/c1-28-16-5-4-11(8-15(16)24)2-3-12-6-13(23)9-14(7-12)29-21-20(27)19(26)18(25)17(10-22)30-21/h2-9,17-27H,10H2,1H3/b3-2+/t17-,18-,19+,20-,21-/m1/s1
Rhapontin (3, 3', 5-trihydroxy-4'-methoxystilbene-3-O-glucoside), a natural stilbenoid glycoside widely distributed in the medicinal plants of Rheum genus in China, has anti-thrombotic, anti-allergic and anti-diabetic activity and can be used as the potent antihyperlipidemic agent. In addition was shown, that rhapontin possessed anti-fibrotic activities and could prevent pulmonary fibrosis in vivo by modulating AMPK activation and suppressing the TGF-β/Smad pathway.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Patents
Sample Use Guides
In a dextran sodium sulfate (DSS)-induced mouse model: oral administration of rhapontin (100mg/kg) significantly attenuated colonic pathological damage and remarkably inhibited infiltration by inflammatory cells, myeloperoxidase (MPO) activity, NLRP3 inflammasome activation and SIRT1 expression in the colon.
Route of Administration:
Oral
It was studied the effect of rhapontin alone at difference dosages (0.1–5 μM) on TGF-β1-mediated extracellular matrix (ECM) deposition in primary lung fibroblast (PLF) cells, on TGF-β1 secretion in LPS -stimulated human THP-1, derived macrophages in vitro. Rhapontin suppressed myofibroblast differentiation in a dose-dependent manner, the significant reduction was observed at the concentration of 5 μM.
SUBSTANCE RECORD
